Upcoming event

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC

Nephron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy

Development of a novel score (RENSAFE) to determine probability of acute kidney injury and renal functional decline post surgery: A multicenter analysis

Preoperative renal parenchyma volume as a predictor of kidney function following nephrectomy of complex renal masses

Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma

ESMO Congress 2023

Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma: Randomized open-label phase III LITESPARK-005 study

Safety and efficacy of two doses of belzutifan in patients with advanced RCC: Results of the randomized phase II LITESPARK-013 study

Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time

European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View

PreviousNext